Insider Selling: Vericel Corp (VCEL) CFO Sells $200,200.00 in Stock

Vericel Corp (NASDAQ:VCEL) CFO Gerard J. Michel sold 10,000 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $20.02, for a total transaction of $200,200.00. Following the sale, the chief financial officer now owns 122,249 shares in the company, valued at approximately $2,447,424.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

VCEL opened at $19.13 on Friday. Vericel Corp has a fifty-two week low of $8.95 and a fifty-two week high of $21.00. The stock has a market cap of $866.69 million, a P/E ratio of -136.63 and a beta of 3.04.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Tuesday, February 26th. The biotechnology company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.04 by $0.07. Vericel had a negative net margin of 8.96% and a negative return on equity of 7.58%. The company had revenue of $31.34 million for the quarter, compared to analyst estimates of $28.69 million. During the same quarter last year, the business earned $0.01 earnings per share. Vericel’s revenue was up 34.2% compared to the same quarter last year. Analysts expect that Vericel Corp will post 0.07 EPS for the current year.



Several research firms recently weighed in on VCEL. Zacks Investment Research lowered shares of Vericel from a “buy” rating to a “hold” rating in a research note on Friday, March 8th. BidaskClub lowered shares of Vericel from a “buy” rating to a “hold” rating in a research note on Friday. Needham & Company LLC lowered shares of Vericel from a “buy” rating to a “hold” rating and set a $17.92 price objective on the stock. in a research note on Thursday, February 28th. Finally, Oppenheimer began coverage on shares of Vericel in a research note on Tuesday, January 29th. They set an “outperform” rating and a $23.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Vericel presently has a consensus rating of “Buy” and a consensus price target of $19.58.

Large investors have recently made changes to their positions in the business. BlackRock Inc. increased its stake in shares of Vericel by 10.8% in the third quarter. BlackRock Inc. now owns 2,865,843 shares of the biotechnology company’s stock valued at $40,551,000 after purchasing an additional 279,408 shares during the period. Meeder Asset Management Inc. boosted its holdings in shares of Vericel by 28.7% in the fourth quarter. Meeder Asset Management Inc. now owns 5,765 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 1,284 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Vericel in the third quarter valued at approximately $4,725,000. Jane Street Group LLC bought a new position in shares of Vericel in the third quarter valued at approximately $239,000. Finally, California Public Employees Retirement System boosted its holdings in shares of Vericel by 26.9% in the second quarter. California Public Employees Retirement System now owns 55,695 shares of the biotechnology company’s stock valued at $540,000 after acquiring an additional 11,795 shares in the last quarter. Institutional investors own 84.18% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Vericel Corp (VCEL) CFO Sells $200,200.00 in Stock” was originally published by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://dakotafinancialnews.com/2019/03/15/insider-selling-vericel-corp-vcel-cfo-sells-200200-00-in-stock.html.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.

Further Reading: How do investors use RSI to grade stocks?

Insider Buying and Selling by Quarter for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply